SINGAPORE– Prestige Biopharma Limited and Vaxine Pty Ltd announced that the two organizations have entered into a memorandum of understanding (MOU) to collaborate on the supply of Vaxine’s COVID-19 Vaccine, Covax-19® (also known as Spikogen®) and on the co-development of COVID-19/influenza combo vaccine.
Vaxine has developed a state-of-the-art recombinant protein vaccine against COVID-19 that is manufactured using insect cells and includes Vaxine’s proprietary Advax polysaccharide adjuvant. This vaccine showed efficacy against infection by the Delta variant in Phase 3 clinical trials and already is in use in the Middle East. In December 2021, the Australian Therapeutic Goods Administration (TGA) granted a provisional determination allowing an application to be lodged for a provisional approval for this COVID-19 vaccine. Regulatory submissions are similarly underway in many other countries in parallel.
Industry experts remain concerned that the next pandemic might be even worse than Covid-19, creating an urgent need to develop strong and affordable pandemic vaccine platforms like the one Vaxine created for its Covid-19 and influenza pandemic vaccine production.
Through this MOU, Prestige and Vaxine will be building a long-term vaccine partnership, initially focused on manufacturing and commercialization of Vaxine’s Covid-19 vaccine and then as Covid-19 enters an endemic phase development of a next generation Covid-19/influenza combo vaccine as well as other vaccine projects.
The MOU will bring together Prestige’s global scale vaccine manufacturing capacity & research expertise with Vaxine’s innovative vaccine technologies including its vaccines against COVID-19, seasonal and pandemic influenza, hepatitis B, Japanese encephalitis, dengue, malaria, allergy and cancer.
